Issues
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkBack Matter
- PDF Icon PDF LinkAdvertising
- PDF Icon PDF LinkEditorial Board
Cancer Research
Table of Contents
Articles
In Vitro Evaluation of the New Anticancer Agents KT6149, MX-2, SM5887, Menogaril, and Liblomycin Using Cisplatin- or Adriamycin-resistant Human Cancer Cell Lines1
Production of Interleukin 1β, a Potent Bone Resorbing Cytokine, by Cultured Human Myeloma Cells
Vimentin Rather Than Keratin Expression in Some Hormone-independent Breast Cancer Cell Lines and in Oncogene-transformed Mammary Epithelial Cells
Cadmium Carcinogenesis in Male Wistar [Crl:(WI)BR] Rats: Dose-Response Analysis of Effects of Zinc on Tumor Induction in the Prostate, in the Testes, and at the Injection Site
Journal Archive
Cancer Research
(1941-Present; volumes 1-current)Published twice monthly since 1987. From 1941-1986, published monthly.
(ISSN 0008-5472)
The American Journal of Cancer
(1931-1940; volumes 15-40)Published quarterly in 1931, bimonthly in 1932, and monthly from 1933 to 1940. The journal changed title to Cancer Research in 1941.
(ISSN 0099-7374)
The Journal of Cancer Research
(1916-1930); volumes 1-14)Published quarterly from 1916 through 1930 (publication was suspended from November 1922 to March 1924). The journal changed title to The American Journal of Cancer in 1931.
(ISSN 0099-7013)
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.